Generation of H7N9-specific human polyclonal antibodies from a transchromosomic goat (caprine) system.
Animals
Animals, Genetically Modified
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ blood
Antibody Formation
/ immunology
Antibody Specificity
/ immunology
Chromosomes, Artificial, Human
Enzyme-Linked Immunosorbent Assay
Genetic Engineering
Goats
Humans
Immunization
Immunoglobulin G
/ genetics
Influenza A Virus, H7N9 Subtype
/ immunology
Neutralization Tests
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
23 01 2019
23 01 2019
Historique:
received:
05
07
2018
accepted:
23
11
2018
entrez:
25
1
2019
pubmed:
25
1
2019
medline:
1
7
2020
Statut:
epublish
Résumé
To address the unmet needs for human polyclonal antibodies both as therapeutics and diagnostic reagents, building upon our previously established transchromosomic (Tc) cattle platform, we report herein the development of a Tc goat system expressing human polyclonal antibodies in their sera. In the Tc goat system, a human artificial chromosome (HAC) comprising the entire human immunoglobulin (Ig) gene repertoire in the germline configuration was introduced into the genetic makeup of the domestic goat. We achieved this by transferring the HAC into goat fetal fibroblast cells followed by somatic cell nuclear transfer for Tc goat production. Gene and protein expression analyses in the peripheral blood mononuclear cells (PBMC) and the sera, respectively, of Tc caprine demonstrated the successful expression of human Ig genes and antibodies. Furthermore, immunization of Tc caprine with inactivated influenza A (H7N9) viruses followed by H7N9 Hemagglutinin 1 (HA1) boosting elicited human antibodies with high neutralizing activities against H7N9 viruses in vitro. As a small ungulate, Tc caprine offers the advantages of low cost and quick establishment of herds, therefore complementing the Tc cattle platform in responses to a range of medical needs and diagnostic applications where small volumes of human antibody products are needed.
Identifiants
pubmed: 30675003
doi: 10.1038/s41598-018-36961-5
pii: 10.1038/s41598-018-36961-5
pmc: PMC6344498
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
366Subventions
Organisme : NIAID NIH HHS
ID : R41 AI131823
Pays : United States
Références
Nat Biotechnol. 2002 Sep;20(9):889-94
pubmed: 12172556
Biologicals. 2008 Nov;36(6):363-74
pubmed: 18789721
Nat Biotechnol. 2009 Feb;27(2):173-81
pubmed: 19151699
PLoS One. 2013 Oct 24;8(10):e78119
pubmed: 24205120
PLoS One. 2014 Mar 06;9(3):e90383
pubmed: 24603704
Sci Transl Med. 2014 Nov 26;6(264):264ra162
pubmed: 25429055
J Intensive Care. 2014 Jul 31;2(1):44
pubmed: 25520846
PLoS One. 2015 Jun 24;10(6):e0130699
pubmed: 26107496
PLoS One. 2015 Sep 30;10(9):e0137786
pubmed: 26422247
Sci Transl Med. 2016 Feb 17;8(326):326ra21
pubmed: 26888429
Sci Rep. 2016 Apr 25;6:24897
pubmed: 27109916
Theriogenology. 2016 Dec;86(9):2302-2311
pubmed: 27650944
J Virol. 2017 Jun 26;91(14):
pubmed: 28468884
Vaccine. 2017 Jul 24;35(33):4079-4087
pubmed: 28669616
Antiviral Res. 2017 Oct;146:164-173
pubmed: 28893603
Clin Infect Dis. 2018 Mar 19;66(7):1116-1119
pubmed: 29272362
Lancet Infect Dis. 2018 Apr;18(4):410-418
pubmed: 29329957
J Reprod Fertil. 1972 Sep;30(3):493-7
pubmed: 4672493
Immunology. 1977 Apr;32(4):373-81
pubmed: 608675